Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease

Back to Jobs

SAN DIEGO , July 26, 2018 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation of the additional Phase 3 trial required to support a submission for U.S.

Apply Now